Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Policosanol, Placebo, Concurrent Exercise Training.
- Who it may be relevant to
- Registry conditions: Dyslipidemia, Elevated Blood Lipids, Physical Fitness, Exercise Training. Basic parameters: 25 years — 59 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Thailand
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Policosanol Supplementation Combined With Concurrent Exercise Training on Physical Fitness and Lipid Profiles in Healthy Volunteers With Elevated Blood Lipid But Not Required Medical Treatment
Overview
This study will evaluate the effects of policosanol supplementation, concurrent exercise training, and their combination on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with elevated blood lipids who are not currently indicated for lipid-lowering medication. Participants will be randomly assigned to one of four groups for 12 weeks: policosanol plus exercise training, policosanol alone, placebo plus exercise training, or placebo without structured exercise training. Participants assigned to the supplementation groups will take policosanol 5 mg per day, while those assigned to the placebo groups will take a matching placebo. Participants assigned to the exercise groups will complete a standardized concurrent exercise training program combining aerobic and resistance exercise. The study will compare changes in physical fitness, lipid profiles, and selected blood biomarkers before and after the intervention. The findings may help determine whether low-dose policosanol, alone or combined with exercise training, can support cardiometabolic health and physical fitness in adults with dyslipidemia.
Detailed description
This clinical trial is designed to examine whether low-dose policosanol supplementation, alone or in combination with concurrent exercise training, can improve physical fitness, muscle recovery, inflammatory responses, and blood lipid profiles in adults with dyslipidemia who are not currently indicated for lipid-lowering medication.
Dyslipidemia is an important modifiable risk factor for cardiovascular disease. Lifestyle modification, including regular exercise, is commonly recommended for individuals with elevated blood lipids before pharmacological treatment is required. Policosanol, a mixture of long-chain aliphatic alcohols mainly derived from plant waxes, has been investigated for its potential effects on lipid metabolism, inflammation, oxidative stress, and exercise-related fatigue. The potential additive effect of combining low-dose policosanol with structured exercise training remains insufficiently established.
This study will compare the independent and combined effects of policosanol supplementation and concurrent exercise training over a 12-week intervention period. The exercise program is designed to integrate aerobic and resistance exercise components. Participants will be assessed at baseline and after the intervention period to determine changes in physical fitness, lipid-related outcomes, and selected biochemical markers related to inflammation and skeletal muscle function.
The study is expected to provide evidence on whether a low dose of policosanol that is regulatory-acceptable (Thai FDA) can be used as an adjunct to exercise training to support cardiometabolic health, physical fitness, and muscle recovery in adults with elevated blood lipid levels. Findings may contribute to future nutrition and exercise recommendations for adults with early-stage dyslipidemia who are not yet receiving lipid-lowering medication.
Interventions
- Dietary supplement Policosanol
Participants assigned to the policosanol intervention will receive policosanol supplementation at a dose of 5 mg per day for 12 weeks. The supplement will be administered orally. This intervention is intended to evaluate the effect of low-dose policosanol on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles in adults with dyslipidemia. - Dietary supplement Placebo
Participants assigned to the placebo intervention will receive a matching placebo product for 12 weeks. The placebo will be prepared to resemble the policosanol supplement in appearance and will be administered in the same manner. This intervention will serve as the control for policosanol supplementation. - Behavioral Concurrent Exercise Training
Participants assigned to the exercise intervention will complete a standardized concurrent exercise training program for 12 weeks. The program will combine aerobic and resistance exercise components and will be performed 3 days per week, approximately 60 minutes per session. This intervention is intended to evaluate the effect of structured exercise training, alone or combined with policosanol supplementation, on physical fitness, muscle recovery, inflammatory markers, and blood lipid profiles.
Primary outcome measures
- Change in Blood Lipid Profile [Time frame: Baseline, week 6, and week 12]
- Change in Body Mass Index [Time frame: Baseline, week 6, and week 12]
- Change in Fat Mass [Time frame: Baseline, week 6, and week 12]
- Change in Lean Mass [Time frame: Baseline, week 6, and week 12]
- Change in Physical Fitness [Time frame: Baseline, week 6, and week 12]
Secondary outcome measures (7)
- Concentration of Interleukin-6 (IL-6) [Time frame: Baseline, week 6, and week 12]
- Concentration of Tumor Necrosis Factor-alpha (TNF-α) [Time frame: Baseline, week 6, and week 12]
- Concentration of Interleukin-10 (IL-10) [Time frame: Baseline, week 6, and week 12]
- Concentration of Interleukin-1 beta (IL-1β) [Time frame: Baseline, week 6, and week 12]
- Concentration of Interleukin-1 Receptor Antagonist (IL-1Ra) [Time frame: Baseline, week 6, and week 12]
- Concentration of Lactate Dehydrogenase A (LDH-A) [Time frame: Baseline, week 6, and week 12]
- Concentration of Serum Coenzyme Q10 [Time frame: Baseline, week 6, and week 12]
Eligibility criteria
Inclusion criteria
- Men and women aged 25 to 59 years.
- BMI between 18.5 and 29.9 kg/m².
- Diagnosed with or presenting with dyslipidemia within the past 3 months, based on laboratory assessment at baseline or a standard laboratory report issued within the past 3 months, according to the National Cholesterol Education Program Adult Treatment Panel III criteria, defined by at least one of the following:
- Total cholesterol ≥ 200 mg/dL;
- Low-density lipoprotein cholesterol ≥ 130 mg/dL and < 190 mg/dL;
- High-density lipoprotein cholesterol < 40 mg/dL in men;
- High-density lipoprotein cholesterol < 50 mg/dL in women;
- Triglycerides ≥ 150 mg/dL.
- Free from chronic or comorbid conditions that contraindicate participation in aerobic or resistance exercise.
- Cleared for physical activity based on the Physical Activity Readiness Questionnaire for Everyone.
- Not regularly physically active during the preceding 3 months, defined as fewer than 3 exercise sessions per week or less than 150 minutes of exercise per week.
- Able and willing to participate in the study procedures and provide written informed consent.
Exclusion criteria
- Current or recent use within the past 3 months of lipid-lowering medications or dietary supplements known to influence lipid metabolism, including statins, fibrates, niacin, omega-3 fatty acids, red yeast rice, or policosanol.
- Known allergy or hypersensitivity to policosanol, sugarcane derivatives, capsule components, or any excipients in the supplement formulation.
- Presence of chronic or comorbid conditions that may make exercise participation unsafe, including but not limited to cardiovascular disease, chronic obstructive pulmonary disease, severe arthritis, osteoporosis, uncontrolled diabetes, gastrointestinal disorders, or neurological impairments affecting movement control.
- High-risk lifestyle factors, including heavy smoking, excessive alcohol consumption, or use of recreational drugs.
Inability to comply with the study protocol, including inability to participate in the exercise program when assigned or inability to attend scheduled follow-up assessments.
\- Refusal or inability to provide written informed consent independently.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Thailand · 1 center
- Institute of Nutrition, Mahidol University — Nakhon Pathom
Identifiers
NCT: NCT07710261 · MU-CIRB 2026/016.1401 · 4839189